eFFECTOR Therapeutics Inc. (EFTR) stock prices were up by 12.37% shortly after market trading commenced on October 8th 2021. This brought the price per share up to USD$12.90 early on in the trading day.
Promising Zotatifin Data
October 7th 2021 saw EFTR stock announce the presentation of new positive data for zotatafin in animal models of triple negative breast cancer (TNBC). The data was presented at the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The treatment is a potent and sequence-selective inhibitor of potent and sequence selective inhibitor of eukaryotic translation initiation factor 4A (eIF4A) mediated translation.
Details of the Results
The study authors found that blocking eIF4A in p53-null models of mouse mammary tumorigenesis with zotatifin results in tumor control. This is via both tumor intrinsic mechanisms, as well as the activation of host immune response in EFTR stock’s trial participants. This activity is additionally potentiated with the addition of chemotherapy. The presentation was entitled “The RNA helicase EIF4A is a therapeutic vulnerability in triple negative breast cancer” and was presented by Dr Zhao in an oral session.
EFTR Stock Ahead of Competition
Historically, successful cancer treatment options have integrated standard of care chemotherapies and immunotherapies. Resistance has been a challenging issue observed with single agents. The company is keen to employ its TNBC models that were developed in its own laboratories for these critical preclinical studies. EFTR stock is hopeful that these trials will lead to breakthroughs which, in turn, will lead to the next generation of clinical trials.
EFTR Stock’s Clinical Study
In the study, zotatifin treatment exhibited a slowing down of tumor growth in six out of eight syngeneic TNBC models, with no apparent toxicity. The treatment also exhibited an inhibition of proliferative and stem cell signaling pathways, including E2F targets, G2/m checkpoints, and NOTCH signaling. Zotatifin induced proteins involved in Interferon- α and Interferon-γ responses. Furthermore, the tandem treatment of zotatifin with the mTOR inhibitor everolimus indicated statistically significant prolonged survival as compared to the use of either agent in isolation.
Future Outlook for EFTR Stock
The company is poised to capitalize on the expanded scope of opportunities afforded to it as a result of the new promising data. EFTR stock is keen to push for the accelerated development and commercialization of its proprietary treatments in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.